To be successful in the pharmaceutical industry, leaders must be willing to take risks. During his conversation with Pharmaceutical Executive, Leonard Mazur kept coming back to this point. According ...

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...

In a conversation with Pharmaceutical Executive, Phesi founder and CEO Gen Li discusses his company’s recent global analysis of clinical trials. While the report once again showed that breast cancer ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Wang, who led AstraZeneca’s China operations for roughly a decade, was detained back in 2024, with his arrest triggering a sharp sell-off in AstraZeneca shares at the time, amid broader investigations ...

Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Sanofi appointed Belén Garijo as its new chief executive officer, marking a leadership transition as the company enters its next strategic phase. Garijo formally assumes the role at the close of ...

The pharmaceutical industry invests billions of dollars 1 in digital tools and technologies. But for all the online surveys, feedback loops, and digital portals introduced to improve the patient ...

What’s missing from many care strategies today is the actual voice of the patient.

FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...

A regulatory setback for Moderna’s next-generation flu vaccine underscores mounting scrutiny of late-stage trial design in the U.S., even as the company pivots to international manufacturing ...